PGEN enters the post-earnings window with an interesting tension: a stock still down 6% on the week, a short position that has been quietly unwinding, and a Q1 revenue beat that confirms Papzimeos is ramping faster than the Street expected.
The earnings print on May 13 was genuinely strong. Q1 revenue came in at $23.25 million, well ahead of the $20.8 million consensus estimate. EPS of -$0.02 matched expectations. That follows a March call where CEO Helen Sabzevari guided Q1 revenues above $18 million — a figure the company then surpassed by more than 25%. The commercial story behind those numbers is straightforward: payer coverage has expanded to roughly 90% of insured US lives, hub patient counts are growing, and the permanent J-code that took effect April 1 is removing a key reimbursement friction point. The next earnings event is pencilled in for June 18.
Short sellers have been closing positions into this print. Short interest as a percentage of free float dropped from roughly 24.5% in early April to 22.2% by May 12 — a meaningful retreat of more than two full percentage points over six weeks. The week alone saw a 4.6% reduction in shares short, the most decisive cover of the past month. Borrowing costs remain entirely unremarkable at 0.55%, and availability in the lending pool has actually loosened sharply this week — utilisation fell from around 50% to just 38%, a multi-month low. That combination of falling short positions and easier borrow conditions suggests the departure of shorts is orderly, not a scramble. The ORTEX short score of 74.2 remains elevated but has eased from 77.3 a week ago, a directional move that tracks the unwinding.
Options positioning has flipped decisively toward calls. The put/call ratio has fallen to 0.81, nearly one standard deviation below its 20-day average of 0.96. Four weeks ago, when the stock was grinding lower and the PCR peaked near 1.18, options traders were buying protection. Now the same traders are reaching for calls — a complete reversal of sentiment in roughly three weeks. The most recent PCR is the lowest of the past month, pointing to growing conviction that the downside was already priced in ahead of the Q1 release.
The analyst picture is stale but uniformly constructive. The most recent changes, both from March 26 in the immediate wake of the full-year print, saw Citizens raise its target to $9 and HC Wainwright lift to $10. Both maintained positive ratings. The mean price target of $9.50 implies more than 130% upside from the current price of $4.08 — a significant gap. That gap itself is worth scrutinising: PGEN remains unprofitable, carries a heavy share count, and the stock has been structurally below analyst targets for some time. Still, the direction of analyst travel over the past year has been consistently upward, with targets stepping from $6 to $8 to $9–$10 in three discrete moves.
The institutional holder list adds a layer of nuance. Third Security holds nearly 30% of shares and has not moved. Point72 disclosed a fresh 5.2% position as of late January, a clean new entry. State Street added over 6 million shares in the most recent period. On the other side, Executive Chairman Randal Kirk sold approximately 4.2 million shares on March 30 at $3.30 — roughly $14 million in aggregate — and his institutional vehicle separately reduced its position. Kirk's selling was extensive across multiple transactions in a single day; the stock has since risen from that $3.30 exit level to $4.08, meaning those sales happened near recent lows. Patient Capital and Tang Capital have also been reducing. The ownership picture is splitting: passive and institutional inflows on one side, insider and active fund outflows on the other.
PGEN's one verifiable historical earnings reaction adds relevant context. At the March 25 full-year print, the stock jumped 24% the next day and extended to a 25.6% gain over five days. The Q1 beat just delivered is arguably of similar quality — a material revenue outperformance on a drug that is accelerating from a low base. Whether the market ascribes a comparable reaction on May 14 depends on how traders have already repositioned; the sharp drop in short positions and the call-skewed options market suggest at least partial anticipation. What to watch from here is whether the Papzimeos revenue trajectory through Q2 holds above the $23 million run-rate, and whether the management team provides any formal guidance framework on the June 18 call — a step they have so far resisted.
See the live data behind this article on ORTEX.
Open PGEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
